Impaired Fasting Plasma Glucose and Type 2 Diabetes Are Related to the Risk of Out-of-Hospital Sudden Cardiac Death and All-Cause Mortality

Jari A. Laukkanen, MD, PhD1,2  
Timo H. Makikallio, MD, PhD2,3  
Kimmo Ronkainen, MD3  
Jouni Karpri, MD, PhD1  
Sudhir Kurl, MD, PhD1

OBJECTIVE—The aim of the study was to determine whether impaired fasting plasma glucose (IFG) and type 2 diabetes may be risk factors for sudden cardiac death (SCD).

RESEARCH DESIGN AND METHODS—This prospective study was based on 2,641 middle-aged men 42–60 years of age at baseline. Impaired FPG level (≥5.6 mmol/L) among nondiabetic subjects (501 men) was defined according to the established guidelines, and the group with type 2 diabetes included subjects (199 men) who were treated with oral hypoglycemic agents, insulin therapy, and/or diet.

RESULTS—During the 19-year follow-up, a total of 190 SCDs occurred. The relative risk (RR) for SCD was 1.51-fold (95% CI 1.07–2.14, P = 0.020) for nondiabetic men with impaired FPG and 2.86-fold (1.87–4.38, P < 0.001) for men with type 2 diabetes as compared with men with normal FPG levels, after adjustment for age, BMI, systolic blood pressure, serum LDL cholesterol, smoking, prevalent coronary heart disease (CHD), and family history of CHD. The respective RRs for out-of-hospital SCDs (137 deaths) were 1.79-fold (1.24–2.58, P = 0.001) for nondiabetic men with impaired FPG and 2.26-fold (1.34–3.77, P < 0.001) for men with type 2 diabetes. Impaired FPG and type 2 diabetes were associated with the risk of all-cause death. As a continuous variable, a 1 mmol/L increment in FPG was related to an increase of 10% in the risk of SCD (1.10 [1.04–1.20], P = 0.001).

CONCLUSIONS—Impaired FPG and type 2 diabetes represent risk factors for SCD.

Diabetes Care 36:1166–1171, 2013

This prospective population-based study was designed to determine if impaired FPG without diagnosed type 2 diabetes is a comparable risk factor for SCD as diabetes is itself. We also studied the predictive accuracy of FPG among nondiabetic subjects and type 2 diabetic subjects with respect to the risk of SCD in the general male population.

RESEARCH DESIGN AND METHODS

Study population

This study was designed to investigate risk predictors for atherosclerotic cardiovascular outcomes in a population-based sample of men from Eastern Finland. The focus of the current prospective study was based on risk markers for SCD. The subjects were a randomly selected sample of 3,433 men 42–60 years of age who resided in the town of Kuopio or its surrounding rural communities (14). Of those who were invited, 2,682 (83%) participated in the study, and those with complete data on FPG and diagnosed type 2 diabetes (2,641 men) were included in the analyses. Baseline examinations were conducted between March 1984 and December 1989. The study was approved by the Research Ethics Committee of the University of Eastern Finland. Each participant gave written informed consent.

Assessment of FPG and type 2 diabetes

FPG was measured using the glucose dehydrogenase method (Merck, Darmstadt, Germany) after proteins had been precipitated with trichloroacetic acid. Fasting serum insulin was measured with a radioimmunoassay (Novo Biolabs; Novo Nordisk, Bagsvaerd, Denmark). An impaired FPG level among nondiabetic subjects was defined according to the recommendations based on the American Diabetes Association (≥5.6 mmol/L = 100 mg/dL) (15). Subjects meeting the following criteria were defined as patients...
with type 2 diabetes: either having regular treatment with an oral hypoglycemic agent, insulin therapy, or having treatment only with diet while also having an FBG level of at least 7.0 mmol/L (16). Dietary treatment indicates that appropriate nutritional advice on diet has been provided for those who were treated only by diet. Insulin resistance was calculated by homeostatic model assessment of insulin resistance (HOMA1-IR), which is defined as follows: HOMA1-IR = fasting plasma insulin \( \mu \text{U/mL} \) × FPG (mmol/L)/22.5 (17).

**Assessment of risk factors**

The lifelong exposure to smoking (cigarette pack-years) was estimated as the product of the number of years smoking and the number of tobacco products smoked daily at the time of examination (18). Resting blood pressure was measured between 8:00 and 10:00 A.M. with a random-zero sphygmomanometer (18). The cholesterol contents of serum lipoprotein fractions and triglycerides were measured enzymatically (Boehringer Mannheim, Mannheim, Germany). Serum HDL cholesterol and its subfractions were separated from fresh serum samples using ultracentrifugation and precipitation. Serum C-reactive protein was measured with an immunometric assay (Immulite High Sensitivity C-Reactive Protein Assay; DPC, Los Angeles, CA).

The use of medications and baseline diseases were assessed by self-administered questionnaires. The diagnosis of chronic diseases was checked during a medical examination by the internist. Alcohol consumption was assessed using the Nordic Alcohol Consumption Inventory (18). BMI was computed as the ratio of weight in kilograms to the square of height in meters. Electrocardiogram and heart rate were recorded at rest and during the exercise testing. The standardized testing protocol included an increase in the workload of 20 W/min with the direct analyses of respiratory gases (Medical Graphics, St. Paul, MN). Cardiorespiratory fitness was defined as the highest value or the plateau of oxygen uptake (19,20).

**Classification of outcomes**

All deaths that occurred by the end of 2008 were checked against the hospital documents, health center wards, and death certificates. Deaths were coded using the ICD-9 or ICD-10 codes. The sources of information included interviews, hospital documents, death certificates, autopsy reports, and medico-legal reports (19,20). There were no losses to follow-up. A death was determined an SCD when it occurred either within 1 h after the onset of an abrupt change in symptoms or within 24 h after the onset of symptoms when clinical findings did not reveal a noncardiac cause of sudden death. SCDs that occurred in out-of-hospital conditions had been accurately documented through hospital documents. The deaths due to aortic aneurysm rupture, cardiac rupture or tamponade and pulmonary embolism, cancer, or other noncardiac comorbidities were not included as SCDs. The diagnostic classification of events was based on symptoms, electrocardiographic findings, cardiac enzyme elevations, autopsy findings (80%), and history of CHD together with the clinical and electrocardiographic findings of the paramedic staff. Thus, we had available all hospital documents, including medical records, laboratory and electrocardiographic findings from the hospital and paramedic staff, and the use of medications and a defibrillator. Nonfatal CHD events were also defined. Coronary events that did not lead to death during the following 24 h were considered a nonfatal CHD event (20). The documents related to the death were cross-checked in detail by two physicians. An independent events committee blinded to clinical data performed the classification of deaths.

**Statistical analysis**

The differences in baseline characteristics were examined using ANOVA and the χ² test. Descriptive data are presented as means and percentages. Risk factors for main outcomes were analyzed using the multivariable Cox model. Subjects with normal (<5.6 mmol/L, reference group) and impaired (≥5.6 mmol/L) FPG levels with type 2 diabetes were entered into the forced Cox proportional hazards models. Cox multivariable models were adjusted for age, BMI, systolic blood pressure, serum LDL cholesterol, smoking, alcohol consumption, prevalent CHD, and a family history of CHD (model 1). Multivariable model 1 was additionally adjusted for three different sets of covariates: C-reactive protein, cardiorespiratory fitness, and ischemic ST changes during exercise electrocardiogram (model 2); serum fibrinogen level, heart rate, and duration of the corrected QT interval on resting electrocardiogram (model 3); and the presence of myocardial infarction, the use of medication for hypertension or dyslipidemia, and the use of β-blockers (model 4). Covariates were selected on the basis of their previously established role as a well-defined predictive factor on the basis of overall evidence and available data.

Relative risks (RRs), adjusted for risk factors, were estimated as antilogarithms of coefficients from multivariable models. The fit of the Cox proportional hazards models was examined by plotting the hazard functions in different categories of risk factors over time. The proportional hazards assumption was verified for all variables by inspection of the plots of the Schoenfeld residual for covariates. The linearity assumption was satisfied for all continuous variables and it was assessed with Martingale residuals for each continuous variable against survival time. The cumulative survival from SCD, according to impaired FPG and type 2 diabetes, was calculated using the Kaplan-Meier method. The attributable risk was calculated as an excess RR for SCD that is related to men with impaired FPG or type 2 diabetes, with the risk among those with normal FPG as the referent. A P value <0.05 was considered statistically significant. Statistical analyses were performed using SPSS 18.0 for Windows.

The C-index was calculated to assess the model discrimination (the ability of the model to correctly identify subjects with respect to SCD) (21). The Harrell C-index was the primary measure of discrimination. On the basis of the C-index, the incremental values of FPG and type 2 diabetes were evaluated with previously documented cardiovascular risk factors. We calculated the integrated discrimination improvement (IDI) and relative IDI for the model with and without FPG (21–23).

**RESULTS**

**Baseline characteristics**

The mean FPG was 5.4 mmol/L (SD 3.6 mmol/L; range 3.4–28.9 mmol/L). The proportion of those with type 2 diabetes was 6.4% (n = 159), of which only six diabetic men were treated with insulin therapy. The number of nondiabetic men with impaired FPG was 501 (20.1%). The mean values of baseline characteristics are shown in Table 1.

**Numbers of outcome events during the follow-up**

The average follow-up time to death or the end of follow-up was 18.8 years (median 20.7 years; interquartile range
Glucose and sudden cardiac death

Table 1—Baseline characteristics

| Characteristics                              | Mean (SD or n) |
|---------------------------------------------|----------------|
| Age (years)                                 | 52.9 (5.1)     |
| BMI (kg/m²)                                 | 26.9 (3.5)     |
| Waist-to-hip ratio                          | 0.95 (0.06)    |
| Smokers (%)                                 | 31.9 (795)     |
| Cigarette smoking (pack-years)*             | 8.4 (16.5)     |
| Alcohol consumption (g/week)                | 74.2 (121.4)   |
| Serum total cholesterol (mmol/L)            | 5.91 (1.07)    |
| Serum LDL cholesterol (mmol/L)              | 4.04 (1.01)    |
| Serum HDL cholesterol (mmol/L)              | 1.29 (0.30)    |
| Serum triglycerides (mmol/L)                | 1.28 (0.82)    |
| Systolic blood pressure (mmHg)              | 134.0 (16.8)   |
| Diastolic blood pressure (mmHg)             | 88.9 (10.5)    |
| FPG (mmol/L)                                | 5.37 (3.38)    |
| Serum insulin (mU/L)                        | 11.6 (7.0)     |
| High-sensitivity C-reactive protein (mmol/L)| 2.28 (3.35)    |
| Cardiorespiratory fitness (ml/kg/min)§      | 30.2 (8.0)     |

Previously diagnosed diseases and family histories % (n)

| Disorder                                      | % (n)  |
|-----------------------------------------------|-------|
| Type 2 diabetes                               | 5.5 (145) |
| CHD                                           | 23.8 (628) |
| History of myocardial infarction              | 7.4 (915) |
| Family history of CHD                         | 49.3 (1,302) |
| History of hypertension                       | 30.1 (795) |
| Family history of hypertension                | 47.4 (1,252) |
| Heart failure                                 | 6.6 (174) |
| Cardiomyopathy†                               | 2.1 (56) |
| Cerebrovascular disease                       | 2.4 (64) |
| Claudication                                  | 3.8 (101) |
| Arrhythmias§                                  | 15.8 (417) |
| Pulmonary disease§                            | 12.5 (330) |
| Cancer                                        | 1.6 (39) |

Regular use of medications [% (n)]

| Medication                                | % (n) |
|-------------------------------------------|-------|
| Antihypertensive medication               | 21.1 (557) |
| Medication for dyslipidemia               | 8.6 (21) |
| β-Blocker                                 | 17.3 (426) |
| Acetyl salicylic acid                     | 6.9 (170) |

*Pack-years denotes the lifelong exposure to smoking, which was estimated as the product of years smoked and the number of tobacco products smoked daily at the time of examination. §Cardiorespiratory fitness was defined as the highest value for or the plateau of oxygen uptake during exercise testing. †The diagnosis is based on clinical findings and symptoms and/or echocardiography. ‡Arrhythmias included extrasystolia, regular or paroxysmal atrial fibrillation, and supraventricular tachycardia. Pulmonary diseases included bronchial asthma, chronic obstructive pulmonary disease, and pulmonary tuberculosis.

18.1–22.6 years). A total of 190 SCDs occurred during the follow-up. Of which, a total of 157 SCDs (82.6%) occurred in out-of-hospital conditions, and 136 (71.9%) out of all documented SCDs were due to documented ventricular tachycardia, ventricular fibrillation, or death, with autopsy revealing no other reason. The number of nonfatal CHD events was 587. Among men with normal FPG levels (<5.6 mmol/L), 146 SCDs were observed (2.8 cases per 1,000 person-years). The numbers of SCDs were 50 (5.6 cases per 1,000 person-years) for nondiabetic men with impaired FPG (≥5.6 mmol/L) and 29 (11.6 cases per 1,000 person-years) for men with type 2 diabetes.

FPG and type 2 diabetes as risk factors for SCD

The RR of SCD was 1.10-fold per 1 mmol/L continuous change in FPG level after adjustment for other risk factors (Table 2). Risk predictors for SCD are shown in Table 2. The respective RR for SCD was 1.32 (95% CI 1.04–1.82, P < 0.001) per 1 mmol/L increment in the subgroup of 2,482 men without type 2 diabetes at baseline.

The RR of SCD was 1.51-fold for nondiabetic men with impaired FPG and 2.86-fold for men with type 2 diabetes as compared with men with normal plasma FPG, after adjustment for age, BMI, systolic blood pressure, serum LDL cholesterol, smoking, alcohol consumption, prevalent CHD, and family history of CHD (model 1) (Table 3). When the multivariable model was further adjusted for C-reactive protein, cardiorespiratory fitness, and ischemic ST changes during exercise electrocardiogram (model 2), the respective RR was 1.45 (95% CI 1.05–2.05, P = 0.030) for nondiabetic men with impaired FPG and 2.33 (1.50–3.62, P < 0.001) for diabetic men as compared with the risk of SCD in study participants with normal FPG levels.

The observed RR did not substantially change, although serum fibrinogen level, heart rate, and duration of the corrected QT interval on resting electrocardiogram were taken into account (model 3). The association of impaired FPG and type 2 diabetes with the risk of SCD remained significant if a previous history of myocardial infarction and the first myocardial infarction during the interim period of the follow-up, the use of medication for hypertension or dyslipidemia, and the use of β-blockers were included into the multivariable model (model 4). Kaplan-Meier curves for nondiabetic men with impaired FPG and type 2 diabetes are presented in Fig. 1.

The RR of out-of-hospital SCD was 1.79-fold for nondiabetic men with IFG and 2.26-fold for men with type 2 diabetes (Table 3). The respective RR of all-cause death was also increased among nondiabetic subjects with impaired FPG and type 2 diabetes (Table 3). Additionally, the adjusted RR of nonfatal CHD events was higher in men with impaired FPG (RR 1.63 [95% CI 1.16–2.31], P = 0.005) and type 2 diabetes (2.49 [1.90–3.27], P < 0.001), as compared with men with normal FPG levels.

The inclusion of FPG in the model with other risk factors (model 1) increased the C-index from 0.757 to 0.761, indicating a modest nonsignificant incremental value. The C-index for the total model was 0.762 after the inclusion of type 2 diabetes instead of FPG. Thus, the C-index with FPG or type 2 diabetes did not markedly differ between the two models that included previously established risk factors. The IDI was 0.006 (P = 0.023), showing the significant level of discrimination improvement when FPG
was added in the model. The relative IDI value for the model was 0.083. A total of 14.7% of the SCD cases in this cohort during the follow-up were attributable to impaired FPG (≥5.6 mmol/L) or type 2 diabetes.

**FPG, insulin resistance, and type 2 diabetes as risk factors for SCD**

The association between impaired FPG, type 2 diabetes, and SCD remained significant even though insulin resistance was taken into account. The RR of SCD was 1.50-fold (95% CI 1.05–2.25, P = 0.035) for nondiabetic men with impaired FPG and 1.91-fold (1.09–3.33, P = 0.022) for men with type 2 diabetes, as compared with men with normal FPG levels, after adjustment for HOMA1-IR as well as age, BMI, systolic blood pressure, serum LDL cholesterol, smoking, alcohol consumption, prevalent CHD, and family history of CHD. In this multivariable model, HOMA1-IR was not statistically significantly related to the risk of SCD.

**CONCLUSIONS**—This study demonstrates that impaired FPG among nondiabetic subjects and type 2 diabetic subjects represents risk factors for SCD. We observed that each 1 mmol/L increment in FPG was related to a 10% elevated risk of SCD.

Sudden cardiac arrest in adults is mainly due to underlying CHD, and the most common electrophysiological mechanism of SCD is ventricular arrhythmias. Previous findings suggest that myocardial as well as electrical abnormalities are likely to influence the risk of SCD (24). Although the exact underlying mechanism is not well known, increased sympathetic activity caused by impaired FPG may decrease the heart rate variability. Cardiac autonomic dysfunction is a complication of the asymptomatic prediabetes state and type 2 diabetes (25,26), and impaired FPG can be considered as a prestage of type 2 diabetes, which suggests the early presence of autonomic nerve dysfunction (25). Increased insulin resistance with elevated glucose levels is associated with a higher resting heart rate and lower heart rate variability, representing the decline of cardiovascular autonomic function (27). Other mechanisms by which impaired FPG and type 2 diabetes may affect SCD risk include intraventricular conduction abnormalities due to autonomic imbalance and disturbed myocardial function (25–28). Other potential factors contributing to the increased risk of SCD observed in subjects with impaired FPG or type 2 diabetes are silent myocardial ischemia, plaque rupture, abnormal cardiac repolarization, and diabetic cardiomyopathy (24). Some studies have found that the hyperglycemic and prothrombotic state could be a factor related to a higher risk of SCD (3,4,29). The association between impaired FPG and SCD may be partly due to a clinically asymptomatic microvascular process as well as macrovascular disease with coronary atherosclerosis (4).

Although the incidence of sudden cardiac arrest is quite low in the general population, the absolute numbers of SCD are high. The definitions of FPG in clinical practice may provide a useful risk marker for SCD in the general population. However, due to the observational nature of this study, it does not allow any estimation of the impact of FPG-lowering therapies on the incidence of SCD. The results suggest that the level of impaired FPG itself may be an important risk factor for out-of-hospital SCD; although the importance of very strict FPG control in the prevention of ventricular arrhythmias would require confirmation from clinical trials. The focus of this study was to show the association of impaired FPG with SCD risk. We explored SCD by incorporating serum measures of hemostatic factors, serum lipids, blood pressure, and inflammatory measures in the multivariable model. The strength of our study includes the availability of autopsy data in 80% of the SCD cases during the long-term follow-up. In our study, the incidence of SCD was somewhat higher than in some of the other lower-risk populations (11,30). The current study has been performed in an area known for its high prevalence of coronary artery disease (as an underlying cause for SCD) in previous

---

**Table 2—Risk factors for SCD among middle-aged men**

| Risk factor                                           | RR* | 95% CI          | P value |
|-------------------------------------------------------|-----|-----------------|---------|
| FPG (per 1 mmol/L)                                    | 1.10| 1.04–1.20       | 0.001   |
| Cigarette smoking (per 10 pack-years)†                | 1.24| 1.16–1.32       | <0.001  |
| Prevalent CHD (yes vs. no)‡                            | 2.71| 2.10–3.63       | <0.001  |
| Systolic blood pressure (per 10 mmHg)                 | 1.13| 1.05–1.22       | 0.001   |
| BMI (per 5 kg/m²)                                     | 1.38| 1.15–1.67       | 0.001   |
| Age (per 1 year)                                      | 1.06| 1.03–1.10       | 0.001   |
| Serum LDL cholesterol (per 1 mmol/L)                  | 1.21| 1.06–1.39       | 0.004   |
| Family history of CHD (yes vs. no)                    | 1.34| 1.01–1.79       | 0.047   |
| Alcohol consumption (per 100 g/week)                  | 1.06| 0.98–1.15       | 0.167   |

*RRs (95% CIs) are based on Cox multivariable model adjusted for all variables shown in the table. †Pack-years denotes the lifelong exposure to smoking that was estimated as the product of years smoked and the number of tobacco products smoked daily at the time of examination. ‡Prevalent CHD includes previous history of myocardial infarction and/or the diagnosis of CHD.

---

**Table 3—RRs of SCD and all-cause death according to the FPG and type 2 diabetes**

| Risk factor                                           | SCD* (190 deaths) | Out-of-hospital SCD* (157 deaths) | All-cause death (734 deaths) |
|-------------------------------------------------------|-------------------|-----------------------------------|-----------------------------|
| Impaired FPG (≥5.6 mmol/L) (n = 501)                   | 1.51 (1.07–2.14)  | 1.79 (1.24–2.38)                  | 1.31 (1.11–2.87)            |
| Type 2 diabetes (n = 159)                              | 2.86 (1.87–4.38)  | <0.001                            | 2.26 (1.34–3.77)            |

*A death was determined as SCD when it occurred either within 1 h after the onset of an abrupt change in symptoms or within 24 h after the onset of symptoms when autopsy data did not reveal a noncardiac cause of sudden death. SCDs that occurred in out-of-hospital conditions were also defined. RRs (95% CIs) are adjusted for age, BMI, systolic blood pressure, serum LDL cholesterol, smoking, alcohol consumption, prevalent CHD, and family history of CHD.
Glucose and sudden cardiac death

Figure 1—The proportions of SCD according to FPG levels and type 2 diabetes. The groups were as follows: 1) men with normal FPG; 2) nondiabetic men with impaired FPG (≥5.6 mmol/L); and 3) men with type 2 diabetes.

decades (31). FPG yielded a modest improvement in SCD prediction when other risk factors were taken into account. There was an improvement in the level of discrimination while using FPG in addition to other risk factors. A discrimination analysis showed a significant level of discrimination between men with and without a known FPG. Our study shows that impaired FPG, which is an easily available everyday clinical method, can be used as a predictive marker for the risk of SCD.

A limitation of this study was that the formal competing risk analyses were not performed. The observed associations between FPG and type 2 diabetes, with the risk of main outcomes including nonfatal CHD events, were statistically significant. The main findings would not have markedly changed even if the formal competing risk analysis was taken into account. Consistently, it has been previously shown that impaired fasting glucose is related to an increased risk of major cardiovascular events (32). The follow-up studies may have been biased by the participants receiving advice on how to change their lifestyle, when appropriate, as well as the reporting of the study findings to their physicians. The single assessment of FPG at baseline may lead to an underestimation, rather than an overestimation, of the prognostic significance of FPG. In clinical practice, however, the assessment of FPG should be repeated to check the effect of dietary and physical activity habits or other therapies. Our representative sample of men makes it possible to generalize the observed results to male populations, but it is important to confirm the results on impaired FPG and the risk of SCD in female populations.

Our results suggest that not only men with type 2 diabetes but also nondiabetic men with impaired FPG have an increased risk of out-of-hospital SCD. Impaired FPG levels can provide valuable information as prevention appears to be a viable approach for substantially decreasing the devastating effects of sudden cardiac arrest in the general population.

Acknowledgments—This study was supported by the Academy of Finland (Helsinki, Finland), the City of Kuopio, and the Finnish Medical Foundation (Helsinki, Finland). No potential conflicts of interest relevant to this article were reported.

J.A.L. analyzed and researched data and wrote the manuscript. T.H.M. and S.K. researched data and wrote the manuscript. K.R. analyzed data and edited the manuscript. J.K. contributed to discussion and reviewed and edited the manuscript. J.L. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

The authors thank the staff of the Kuopio Research Institute of Exercise Medicine and the Research Institute of Public Health, University of Eastern Finland, for data collection in the study.

References

1. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation 1998;98:2334–2351
2. Curb JD, Rodríguez BL, Burchfiel CM, Abbott RD, Chiu D, Yano K. Sudden death, impaired glucose tolerance, and diabetes in Japanese American men. Circulation 1995;91:2591–2595
3. Balkau B, Jouven X, Ducimetière P, Eschwége E. Diabetes as a risk factor for sudden death. Lancet 1999;354:1968–1969
4. Jouven X, Lemaitre RN, Rea TD, Sotoodehnia N, Empara JP, Siscovich DS. Diabetes, glucose level, and risk of sudden cardiac death. Eur Heart J 2005;26:2142–2147
5. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001;345:1473–1482
6. Müller D, Agrawal R, Arntz HR. How sudden is sudden cardiac death? Circulation 2006;114:1146–1150
7. Haffner SM, Lehto S, Ronnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229–234
8. Escobedo LG, Caspersen CJ. Risk factors for sudden coronary death in the United States. Epidemiology 1997;8:175–180
9. Sexton PT, Walsh J, Jamrozik K, Parsons R. Risk factors for sudden unexpected cardiac death in Tasmanian men. Aust NZ J Med 1997;27:45–50
10. Jouven X, Desnos M, Guerot C, Ducimetière P. Predicting sudden death in the population: the Paris Prospective Study I. Circulation 1999;99:1978–1983
11. Kannel WB, Wilson PW, D’Agostino RB, Cobb J. Sudden coronary death in women. Am Heart J 1998;136:205–212
12. Suonen O, Reunanen A, Knekt P, Aromaa A. Risk factors for sudden and non-sudden coronary death. Acta Med Scand 1988;225:19–25
13. Wannamethee G, Shaper AG, Macfarlane PW, Walker M. Risk factors for sudden cardiac death in middle-aged British men. Circulation 1993;91:1749–1756
14. Salonen JT. Is there a continuing need for longitudinal epidemiologic research? The Kuopio Ischaemic Heart Disease Risk Factor Study. Ann Clin Res 1988;20:46–50
15. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012;35(Suppl. 1):S64–S71
16. Salonen JT, Nyyssönen K, Tuomainen TP, et al. Increased risk of non-insulin dependent diabetes mellitus at low plasma vitamin E concentrations: a four year follow up study in men. BMJ 1995;311:1124–1127
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419
18. Lakka TA, Venäläinen JM, Rauramaa R, Salonen R, Tuomilehto J, Salonen JT. Relation of leisure-time physical activity and cardiorespiratory fitness to the risk of acute myocardial infarction. N Engl J Med 1994;330:1549–1554
19. Laukkanen JA, Mälskallio TH, Rauramaa R, Kivimäki M, Ronkainen K, Kurl S. Cardiorespiratory fitness is related to the risk of sudden cardiac death: a population-based follow-up study. J Am Coll Cardiol 2010;56:1476–1483
20. Laukkanen JA, Kurl S, Salonen R, Rauramaa R, Salonen JT. The predictive value of cardiorespiratory fitness for cardiovascular events in men with various population profiles: a prospective population-based cohort study. Eur Heart J 2004;25:1428–1437
21. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing error. Stat Med 1996;15:361–387
22. Hlatky MA, Greenland P, Arnett DK, et al.; American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009;119:2408–2416
23. Pencina MJ, Larson MG, D’Agostino RB. Choice of time scale and its effect on significance of predictors in longitudinal studies. Stat Med 2007;26:1343–1359
24. Kucharska-Newton AM, Couper DJ, Pankow JS, et al. Diabetes and the risk of sudden cardiac death, the Atherosclerosis Risk in Communities Study. Acta Diabetol 2010;47(Suppl. 1):161–168
25. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003;26:1353–1359
26. Singh JP, Larson MG, O’Donnell CJ, et al. Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). Am J Cardiol 2000;86:309–312
27. Balcioğlu S, Arslan U, Türkoğlu S, Ozdemir M, Cengel A. Heart rate variability and heart rate turbulence in patients with type 2 diabetes mellitus with versus without cardiac autonomic neuropathy. Am J Cardiol 2007;100:890–893
28. Whitsel EA, Raghunathane TE, Pearce RM, et al. RR interval variation, the QT interval index and risk of primary cardiac arrest among patients without clinically recognized heart disease. Eur Heart J 2001;22:165–173
29. Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part 1. Circulation 2003;108:1527–1532
30. Albert CM, Ruskin JN. Risk stratifiers for sudden cardiac death (SCD) in the community: primary prevention of SCD. Cardiovasc Res 2001;50:186–196
31. Keys A, Menotti A, Aravanis C, et al. The seven countries study: 2,289 deaths in 15 years. Prev Med 1984;13:141–154
32. Smith NL, Barzilay JI, Kronmal R, Lumley T, Enquobahrie D, Psaty BM. New-onset diabetes and risk of all-cause and cardiovascular mortality: the Cardiovascular Health Study. Diabetes Care 2006;29:2012–2017